Drug Type T-lymphocyte cell therapy |
Synonyms |
Target |
Mechanism ITGB7 inhibitors(integrin subunit beta 7 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapse multiple myeloma | Phase 2 | JP | 18 Feb 2021 | |
Multiple Myeloma | Discovery | JP | - | 02 Dec 2020 |